Trump tariffs on generic drugs
Analysis based on 6 articles · First reported Jul 21, 2026 · Last updated Jul 22, 2026
The tariff announcement pressures generic drug manufacturers to relocate production, potentially increasing drug costs and supply chain disruptions. Indian pharmaceutical companies face significant export risks, while major US drugmakers with agreements may benefit from reduced competition.
President Donald Trump announced on July 21, 2026, that generic drug manufacturers will have two years to move production to the United States or face a 100% import duty starting August 2028, doubling to 200% in August 2029. The move aims to reshore generic pharmaceutical production. The administration previously launched a probe under Section 232 of the Trade Expansion Act. Major drugmakers like Merck & Co. and Eli Lilly and Company have struck agreements to avoid tariffs on patented drugs. Generic makers, including Novartis — Sandoz, Sun Pharma, and Viatris, face higher risks due to thin margins. India, the largest exporter of generic medicines to the US, is significantly affected, with over 40% of its exports to the US potentially impacted. The Supreme Court earlier deemed some emergency duties unlawful.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard